In fact, DPD deficiency in bladder cancer cells has been associated with gemcitabine sensitivity, whereas the overexpression of DPYD (DPD-coding gene) was linked to gemcitabine resistance via its catalytic inactivation [8] (Figure 2). Here, DPYD is linked to urinary bladder cancer.